New combo therapy aims to tame rare liver disease in Long-Term trial
NCT ID NCT06755541
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the long-term safety of combining fenofibrate with standard treatment (ursodeoxycholic acid) in 150 adults with primary biliary cholangitis, a chronic liver disease. Participants previously completed a related study and will take fenofibrate capsules daily. Researchers will monitor side effects, deaths, liver transplants, and liver enzyme levels to see if the combination is safe and tolerable over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fenofibrate and ursodeoxycholic acid
What this could lead to
If it works, this could provide a safe long-term treatment option to help control PBC and reduce the need for liver transplants.
What could go wrong
This is an open-label study with no placebo group, so results may be less reliable. Side effects from fenofibrate are possible, and it may not improve outcomes for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••